AstraZeneca Withdraws Zactima from Consideration of FDA Approval for Advanced NSCLC
AstraZeneca (AZ) just issued a press release noting that they are withdrawing their application for the "multi-kinase inhibitor" Zactima (vandetanib) to receive FDA approval to be given along with chemo in advanced NSCLC right now.